» Articles » PMID: 31406252

CircKDM4C Suppresses Tumor Progression and Attenuates Doxorubicin Resistance by Regulating MiR-548p/PBLD Axis in Breast Cancer

Overview
Journal Oncogene
Date 2019 Aug 14
PMID 31406252
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidence has indicated that circular RNAs (circRNAs) play a critical role in cancer development. However, only a small number of circRNAs have been experimentally validated and functionally annotated. In this study, using a high-throughput microarray assay, we identified a novel circRNA, circKDM4C, which was downregulated in breast cancer tissues with metastasis. Furthermore, we analyzed a cohort of breast cancer patients and found that circKDM4C expression was decreased in breast cancer tissues, and lower circKDM4C expression was associated with poor prognosis and metastasis in breast cancer. Functionally, we demonstrated that circKDM4C significantly repressed breast cancer proliferation, metastasis, and doxorubicin resistance in vitro and in vivo. Mechanistically, using a dual-luciferase activity assay and AGO2 RNA immunoprecipitation, circKDM4C was identified as a miR-548p sponge. We also found that PBLD was a direct target of miR-548p, which functioned as a tumor suppressor in breast cancer. Moreover, miR-548p overexpression was able to reverse the circKDM4C-induced attenuation of malignant phenotypes and elevated expression of PBLD in breast cancer cells. Taken together, our data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circKDM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients.

Citing Articles

Exploring extracellular RNA as drivers of chemotherapy resistance in cancer.

Khan Y, Hussain M, Ramalingam P, Fatima R, Maqbool M, Ashique S Mol Biol Rep. 2025; 52(1):142.

PMID: 39836259 DOI: 10.1007/s11033-025-10263-2.


The role of circRNAs in resistance to doxorubicin.

Sanati M, Ghafouri-Fard S Cell Commun Signal. 2024; 22(1):572.

PMID: 39614315 PMC: 11607985. DOI: 10.1186/s12964-024-01952-9.


PBLD enhances antiviral innate immunity by promoting the p53-USP4-MAVS signaling axis.

Chu F, Hou P, Zhu H, Gao Y, Wang X, He W Proc Natl Acad Sci U S A. 2024; 121(49):e2401174121.

PMID: 39589880 PMC: 11626120. DOI: 10.1073/pnas.2401174121.


Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.

Liu Y, Zou Y, Ye Y, Chen Y Cancer Med. 2024; 13(22):e70410.

PMID: 39558881 PMC: 11574469. DOI: 10.1002/cam4.70410.


PBLD promotes IRF3 mediated the type I interferon (IFN-I) response and apoptosis to inhibit viral replication.

Zhu H, Hou P, Chu F, Li X, Zhang W, Sun X Cell Death Dis. 2024; 15(10):727.

PMID: 39362857 PMC: 11450232. DOI: 10.1038/s41419-024-07083-w.


References
1.
Jones S . Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008; 8(3):224-33. DOI: 10.3816/CBC.2008.n.025. View

2.
Maishman T, Cutress R, Hernandez A, Gerty S, Copson E, Durcan L . Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study. Ann Surg. 2016; 266(1):165-172. PMC: 5639998. DOI: 10.1097/SLA.0000000000001930. View

3.
OReilly E, Gubbins L, Sharma S, Tully R, Guang M, Weiner-Gorzel K . The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015; 3:257-75. PMC: 4661576. DOI: 10.1016/j.bbacli.2015.03.003. View

4.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T . Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018; 173(4):879-893.e13. PMC: 6132060. DOI: 10.1016/j.cell.2018.03.041. View

5.
Cocquerelle C, Mascrez B, Hetuin D, Bailleul B . Mis-splicing yields circular RNA molecules. FASEB J. 1993; 7(1):155-60. DOI: 10.1096/fasebj.7.1.7678559. View